Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

@article{Ogura2013PhaseIS,
  title={Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.},
  author={Michinori Ogura and Kensei Tobinai and Kiyohiko Hatake and Toshiki Uchida and Tatsuya Suzuki and Yukio Kobayashi and Masakazu Mori and Yasuhito Terui and M. Yokoyama and Tomomitsu Hotta},
  journal={Cancer science},
  year={2013},
  volume={104 1},
  pages={105-10}
}
As CD20 has become an established target for treating B-cell malignancies, there is interest in developing anti-CD20 antibodies with different functional activity from rituximab that might translate into improved efficacy. Obinutuzumab (GA101) is a glycoengineered, humanized type II anti-CD20 monoclonal antibody that has demonstrated superior activity to type I antibodies in preclinical studies and is currently being investigated in phase III trials. In this phase I dose-escalating study in… CONTINUE READING
17 Citations
42 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 42 references

A phase I study of obinutuzumab induction followed by two years of maintenance in patients with relapsed CD 20positive B - cell malignancies

  • SE Assouline, DA Stewart
  • Blood
  • 2012

glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

  • L Sehn, SE Assouline, DA Stewart
  • Blood
  • 2012

induction followed by two years of maintenance in patients with relapsed CD20-positive B-cell malignancies

  • BD Cheson, SJ Horning, B Coiffier
  • Blood
  • 2012

Comparison of the in vitro effects of the antiCD 20 antibodies rituximab and GA 101 on chronic lymphocytic leukaemia cells

  • M Patz, P Isaeva, N Forcob
  • Br J Haematol
  • 2011

Efficacy and safety of obinutuzumab ( GA 101 ) monotherapy in relapsed / refractory indolent non - Hodgkin ’ s lymphoma : results from a phase I / II study ( BO 20999 )

  • G Salles, F Morschhauser
  • Blood
  • 2011

Encouraging activity of obinutuzumab ( GA 101 ) monotherapy in relapsed / refractory aggressive non - Hodgkin ’ s lymphoma : results from a phase II study ( BO 20999 )

  • F Morschhauser, G Cartron
  • Blood
  • 2011

GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

  • A Ivanov, SA Beers, CA Walshe
  • Blood
  • 2011

Hodgkin’s lymphoma: results from a phase I/II study (BO20999)

  • L Sehn, A Goy, FC Offner
  • Blood
  • 2011

Similar Papers

Loading similar papers…